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Abstract. In December 2019, a novel severe acute respiratory syndrome (SARS) from a new 
coronavirus (SARS-CoV-2) was recognized in the city of Wuhan, China. Rapidly, it became an 
epidemic in China and has now spread throughout the world reaching pandemic proportions. High 
mortality rates characterize SARS-CoV-2 disease (COVID-19), which mainly affects the elderly, 
causing unrestrained cytokines-storm and subsequent pulmonary shutdown, also suspected micro 
thromboembolism events. At the present time, no specific and dedicated treatments, nor approved 
vaccines, are available, though very promising data come from the use of anti-inflammatory, anti-
malaria, and anti-coagulant drugs. In addition, it seems that males are more susceptible to SARS-
CoV-2 than females, with males 65% more likely to die from the infection than females. Data from 
the World Health Organization (WHO) and Chinese scientists show that of all cases about 1.7% of 
women who contract the virus will die compared with 2.8% of men, and data from Hong Kong 
hospitals state that 32% of male and 15% of female COVID-19 patients required intensive care or 
died. On the other hand, the long-term fallout of coronavirus may be worse for women than for men 
due to social and psychosocial reasons. Regardless of sex- or gender-biased data obtained from 
WHO and those gathered from sometimes controversial scientific journals, some central points 
should be considered. Firstly, SARS-CoV-2 has a strong interaction with the human ACE2 receptor, 
which plays an essential role in cell entry together with transmembrane serine protease 2 
(TMPRSS2); it is interesting to note that the ACE2 gene lays on the X-chromosome, thus allowing 
females to be potentially heterozygous and differently assorted compared to men who are definitely 
hemizygous. Secondly, the higher ACE2 expression rate in females, though controversial, might 
ascribe them the worst prognosis, in contrast with worldwide epidemiological data. Finally, several 
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genes involved in inflammation are located on the X-chromosome, which also contains high number 
of immune-related genes responsible for innate and adaptive immune responses to infection. Other 
genes, out from the RAS-pathway, might directly or indirectly impact on the ACE1/ACE2 balance 
by influencing its main actors (e.g., ABO locus, SRY, SOX3, ADAM17). Unexpectedly, the higher 
levels of ACE2 or ACE1/ACE2 rebalancing might improve the outcome of COVID-19 in both sexes 
by reducing inflammation, thrombosis, and death. Moreover, X-heterozygous females might also 
activate a mosaic advantage and show more pronounced sex-related differences resulting in a sex 
dimorphism, further favoring them in counteracting the progression of the SARS-CoV-2 infection. 
Keywords: SARS-CoV-2; COVID-19; ACE1; ACE2; RAS-pathway; TMPRSS2; sex/gender-gap; lung 
shut-down; prognostic molecular/genetic markers; inflammation; thrombosis 
 
1. Introduction 
SARS-CoV-2 belongs to the β-coronavirus family and the associated severe acute respiratory 
syndrome (SARS), like the previous SARS-CoV and Middle East respiratory syndrome (MERS-CoV), 
it may cause life-threatening diseases [1–6]. Data from past epidemiological studies match with 
emerging observations, indicating a large, sex-dependent gap in disease infection and outcomes for 
SARS-CoV-2 disease (COVID-19) as for previous SARS [7,8]. Moreover, people aged 60 and over 
suffer worse outcomes with mortality rates above 50% [9,10], and sex differences in incidence and 
higher fatality rates in males compared to females were also peculiar to earlier SARS. Conversely, 
infants and children experience mild symptoms and a better prognosis, without sex differences, and 
with a mildly elevated proinflammatory cytokines-storm in the early phase of the illness [11,12]. 
Accordingly, thrombosis due to coagulation unbalance or inherited or acquired thrombophilia is a 
rare event among children [13–17], and this could in part account for the micro-thromboembolic 
events or cardiac injury found in the elderly severest cases as well the rarer disseminated 
intravascular coagulation (DIC) [18–20], strongly substantiating heparin-based anticoagulant 
treatments in the selected severe cases [18,21,22]. On the other hand, the severity of COVID-19 
worsens with advancing age for both sexes, possibly due to a dysregulation of the immune response, 
a difference in sex-hormones that has become less evident with age between sexes, or a considerable 
unbalancing in the coagulation/fibrinolytic system and endothelial dysfunction with aging [23–26]. 
Accordingly, in a mouse model, gonadectomy did not affect disease outcome in male mice, whilst 
ovariectomy or estrogen receptor antagonists caused increased mortality in females after SARS-CoV 
infection [7]. This observation also strongly agrees with the fact that females mount stronger innate 
and adaptive immune responses and are relatively more resistant to virus infections than males. The 
difference in the copy number of X-linked genes involved in the immune response and the presence 
of genes dedicated to disease susceptibility in males and females may account for any other possible 
sex advantage [27–30]. As concerns sex hormones, testosterone suppresses innate immune responses, 
whilst estrogens have immune-suppressive effect at higher levels and immune-stimulant activity at 
lower levels [27,31–33], with peculiar functions to contrast virus replication in selected tissues such 
as nasal epithelial cells in humans [34]. 
Less investigated, is whether differences in the efficiency of the SARS-CoV-2 cell-entry might 
account for at least part of the observed sex-gap. It has been reported that SARS-CoV-2 enters human 
cells using the SARS-CoV receptor ACE2 and a specific transmembrane serine protease 2 (TMPRSS2) 
for the spike (S) protein priming [35], an observation that makes the two biomolecules promising 
therapeutic targets, useful for establishing prevention programs [35–37]. It has been described how a 
modest ACE2 expression characterizes the upper human respiratory tract and that this should limit 
the receptivity of the virus [38,39]. It is controversial whether Metallopeptidase domain 17 (ADAM17, 
also known as TNFα-converting enzyme, TACE), involved in the ACE2 ectodomain shedding, by 
increasing the amount of soluble ACE2 might or might not counteract the virus entry and/or 
exclusively contribute to ACE1/ACE2 unbalancing, inflammation and thrombosis [40]. Furthermore, 
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estrogens increase ADAM17 and ADAM10 expression levels, two putative shedders also responsible 
for many ectodomain cleavages in atherosclerosis [41], suggesting their protective role against 
cardiovascular events in females, a mechanism potentially accounting for the observed COVID-19 
sex-disparity. 
The efficiency in the ACE2-receptor/S-protein recognition and interaction is a key determinant 
for the success of viral infection and receptivity [35]. Recently, the S-protein/ACE2 interface has been 
elucidated at the atomic level and several crucial amino acid residues are recognized to correctly 
achieve the homo-dimerization process [42]. Therefore, proper ACE2 functionality is essential for 
both virus cell entry and local pulmonary homeostasis, and although it has been previously described 
that polymorphisms in the ACE2 gene do not affect the outcome of SARS [43], females might have  a 
higher degree of heterodimer assembling than males, which in turn might show different affinity for 
the SARS-CoV-2 spike receptor. 
Similarly, single nucleotide polymorphisms (SNPs) within the TMPRSS2 gene (21q22.3) can also 
have a greater role in the general population (rs2070788, rs7364083, rs9974589) and in a sex-oriented 
perspective (rs8134378) hypothesizing that higher expression in males might favor virus membrane 
fusion, TMPRSS2 being an androgen responsive gene [44,45] in line with previous GWAS on 
A(H1N1) and A(H7N9) influenza [46]. Conversely, estrogen fall in postmenopausal females in turn 
affects TMPRSS2 expression, the gene also being responsive to estrogens [47]. 
Finally, ACE1 and ACE2 cooperate in the renin–angiotensin system (RAS) to balance the local 
vasoconstrictor/proliferative (ACE1/Ang-II/AT1-axis) and vasodilator/antiproliferative 
(ACE2/Ang1-7/MAS-axis) actions. This results in the protection of organs and blood vessels by 
anticoagulant, anti-inflammatory, anti-proliferation, anti-fibrosis, anti-alveolar epithelial cell 
apoptosis, and anti-oxidative stress activities antagonizing the Ang-II effects (Figure 1). 
 
Figure 1. Schematic representation of the renin–angiotensin system (RAS)-pathway in which 
ACE1/Ang-II/AT1R-axis and ACE2/Ang 1-7/Mas-axis are shown. On the right of the panel, the SARS-
CoV-2-mediated suppression of the ACE2 receptor and the cleavage activity of ADAM17 on ACE2 
are shown. ADAM17: Metallopeptidase domain 17; ARBs: Angiotensin receptor blockers; MRAs: 
mineralocorticoid receptor antagonists. 
Therefore, the coexistence of inherited predispositions or common gene polymorphisms in the 
ACE1 and ACE2 genes that affect their mutual expression levels might lead to increased capillary 
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permeability, coagulation, fibrosis, and apoptosis in the alveolar cells, accelerating lung damage and 
pulmonary shut-down triggered/worsened by the SARS-CoV-2 infection. 
Most likely, it is plausible that a combination of the mechanisms described above might 
influence the multistep pathogenesis and the age/sex-gaps of such a complex infection and 
progression, considering also that ACE2 (locus Xp22.2) and Ang-II receptor type 2 gene (AGTR2, alias 
AT2, locus Xq23) are both located on the X-chromosome. Essentially, X-linked heterozygous alleles 
could activate in females a mosaic advantage and a greater sexual dimorphism that might counteract 
viral infection, local inflammation due to cytokine storms and severe outcomes. 
In the present work, we will address the hypotheses suggested above and reveal the main 
underlining genetic mechanisms with the hope that a sex-oriented approach will add new insights 
for a better understanding of COVID-19 also in the general population. 
2. ACE1/ACE2 Pathway and Acute Respiratory Distress Syndrome (ARDS) 
The renin–angiotensin system (RAS) acts as a homeostatic regulator of the vascular function, 
including blood pressure and volume control, starting with renin (REN) mediating the 
transformation of angiotensinogen (AGT) to angiotensin I (Ang-I). Indirectly, RAS is also responsible 
for local tissue homeostasis by anti-inflammatory, anti-coagulant, anti-proliferation, anti-fibrosis, 
anti-apoptosis of epithelial cells, and anti-oxidative stress activities, also controlling the local trophic 
responses to a range of stimuli, viruses included [48,49]. 
The angiotensin I-converting enzyme (ACE1) and the more recently discovered homologue 
ACE2 [50,51], are two antagonist enzymes of the RAS pathway that act and counterbalance each other 
[52]. The main role of ACE1 is the conversion of angiotensin I to angiotensin II (Ang-I > Ang-II), the 
latter being a powerful peptide causing complex processes such as vasoconstriction, inflammation, 
fibrosis and proliferation via the AT1-receptor. Conversely, ACE2 firstly converts Ang-I to Ang 1–9, 
that is then converted by ACE1 in the vasodilator peptide Ang 1–7. Moreover, ACE2 directly converts 
Ang-II to Ang 1–7 and this latter by acting on MAS-receptor exerts organ protection, antagonizing 
the biological effects of Ang-II [50–52]. Moreover, a high ACE2/ACE1 ratio protects against 
endothelial dysfunctions and vascular pathologies, exogenous ACE2 activation promotes 
antithrombotic activity, and the known antithrombotic properties of captopril (ACE inhibitor) and 
losartan (AT1-receptor blocker) are attenuated by a selective Ang 1–7 receptor antagonist [53,54]. 
ACE2 is a key molecule for the tuning of the RAS pathway under both healthy and pathological 
conditions. It has been recently demonstrated that SARS-CoV-2 uses the same receptor (ACE2) as 
SARS-CoV to enter cells in combination with the action of the serine protease TMPRSS2 for S-protein 
priming [35]. ACE2 is expressed in several tissues, including endothelium, lung, heart, intestine, and 
kidney and, as recently demonstrated, on the epithelial cells of oral mucosa and the tongue [36], 
sharing both tissue expression sites and high sequence identity with the homologue ACE1 [50,51]. 
Anomalous tuning of the ACE1/ACE2 pathway contributes to the development of several complex 
pathological conditions such as hypertension, atherosclerosis, thrombosis, heart or kidney failure, 
and severe acute respiratory distress [48]. In the lung, ACE1 is highly expressed, and ACE2 is mainly 
clustered in type-II alveolar cells [36,55–57]. During acute respiratory distress syndrome (ARDS), a 
local RAS unbalance cannot maintain appropriate oxygenation, thus inducing pulmonary edema, 
inflammation, and hyper-proliferation, establishing in turn severe pulmonary shutdown [48,52,58]. 
The observations from the previous SARS epidemic (2003–2009) that some coronaviruses use 
heparan sulfate as a receptor entry by acquiring heparan sulfate-binding sites, and that the heparin 
molecule acts as competitor preventing the binding of the spike protein to the host cell, inhibiting 
infection rate and mortality, are a valuable rationale to start heparin treatment in selected COVID-19 
patients [59–62]. This approach might have a double result, to reduce virus entry and avert 
thrombotic complications or organ dysfunctions [18,21,22]. 
Interestingly, in ARDS animal models, ACE2 knockdown mice experience more severe 
symptoms [58]. ACE2 gene deletion causes progressive cardiac fibrosis [63], whereas ACE2 deficient 
mice result in renal injury and glomerulosclerosis [64,65]. These alterations are reversed or 
ameliorated by treatment with ACE-inhibitors or Ang-receptors blocker (ARBs) [37,63,66,67], 
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whether or not they are combined with infusion of a soluble form of recombinant human ACE2 
(rhACE2) [68–70]. Intuitively, this strategy could also be a possible treatment for COVID-19 patients 
with a double effect: excessive soluble rhACE2 could competitively bind and neutralize the SARS-
CoV-2 virus, and rescue the cellular ACE2 activity counteracting unescapably unrestrained ACE1 
activity to contrast lung injury. In summary, the ACE1/ACE2 balance is crucial in contrasting organ 
dysfunction, so a direct or indirect increase in ACE2 expression together with a modulation of ACE1 
activity may be helpful to avoid pulmonary disease progression (Figure 2) [37,58,71–74]. Accordingly, 
several international societies recommend not to stop treatments with RAS pathway antagonists in 
cardiovascular disease patients [40], and a recent editorial comments on several publications 
discussing the positive effects of RAS inhibitors during COVID-19 [75]. 
 
Figure 2. Schematic representation of lung alveolar in presence of normal homeostasis (left) 
characterized by a balanced ACE1/ACE2 pathway, and during SARS-CoV-2 infection condition 
(right) in which SARS-CoV-2 mediated suppression of ACE2 receptor causes ACE1/ACE2 unbalance 
responsible for RAS over-activation and pulmonary shut-down. 
Finally, other genes directly or indirectly regulate the RAS pathway (Table 1). Firstly, ADAM17 
by promoting the detaching of ACE2 cell receptor might contribute by downregulating the 
ACE2/Ang1-7/Mas axis, and in a sex-oriented perspective, SRY (Y-chromosome) and SOX3 (X-
chromosome) both by upregulating AGT, and downregulating ACE2, AT2, and MAS. Conversely, 
SRY upregulates, whilst SOX3 downregulates, the REN promoter, thus being a potentially 
detrimental step in limiting the global rate of the RAS system that is particularly frail in males [76,77]. 
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Table 1. Main genes directly or indirectly involved in the Renin Angiotensin System homeostasis. 
Gene HGNC ID Name Locus 
AGT 333 Angiotensinogen 1q42.2 
REN 9958 Renin 1q32.1 
ACE1 2707 Angiotensin I converting enzyme  17q23.3 
ACE2 13557 Angiotensin I converting enzyme 2 Xp22.2 
AGTR1 (AT1) 336 Angiotensin II receptor type 1 3q24 
AGTR2 (AT2) 338 Angiotensin II receptor type 2 Xq23 
MAS1 6899 MAS1 proto-oncogene 6q25.3 
ABO 79 
α 1-3-N-acetylgalactosaminyltransferase 
α 1-3-galactosyltransferase 
9q34.2 
ADAM17 195 
Metallopeptidase domain 17 
TNFα-converting enzyme (TACE) 
2p25.1 
SRY 11311 Sex determining region Y Yp11.2 
SOX3 11199 SRY-box transcription factor 3 Xq27.1 
HGNC: Human Gene Nomenclature Committee of the Human Genome Organisation (HUGO). 
ACE1 and ACE2 Genes 
The ACE1 gene maps on chromosome 17q23.3, is 21.32 kb-long, and comprises 26 exons 
(Genbank, NT 010783). NCBI records (https://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=1636) 
include hundreds of intragenic gene variants: most of them are single nucleotide polymorphisms 
(SNPs), a minor part of which are located in the coding region, and few of them are missense 
mutations. Interestingly, the gene encodes two isoforms of ACE1 with two different promoters and 
alternative splicing, and the structure of the ACE1 gene may be the result of a duplication of an 
ancestral gene [78]. 
Among the several gene variants, the more investigated is an insertion/deletion (I/D) defined by 
NCBI [79] as a sequence of 287-bp I/D in the Alu-sequence of intron 16 in the ACE1 gene and is 
represented by four individual SNPs (rs4646994, rs1799752, rs4340 and rs13447447). It is generally 
associated with the expression level of ACE1 [80], with the D/D genotype having the highest 
serum/tissue ACE1 levels, the I/D genotype showing intermediate levels, and the I/I genotype the 
lowest levels [81]. Interestingly, the Online Mendelian Inheritance in Man (OMIM), a catalogue of 
human genes and genetic disorders particularly focused on gene–phenotype relationships, reports 
that this gene may be associated with SARS progression, assuming that the D-allele can be considered 
a genetic predisposition affecting the progression from pneumonia to SARS, as reported in a study 
with Vietnamese SARS patients [82]. Other studies have confirmed these outstanding data [82–84], 
although current conclusions are still controversial [43,85,86]. 
Although about 60% of the ACE1 levels seem to be determined by the ACE1 I/D polymorphism, 
it is extremely interesting that there is a significant sex-difference in serum ACE1 activity/level, which 
is lower among females in both healthy and pathological conditions [81,87–89]. This evidence, 
together with the observation that the ACE1 I-allele seems to be overrepresented among females, and 
that the D-allele (associated with a high level of ACE1) seems more prone to express even higher 
levels among males, suggests a higher chance to have ACE1/ACE2 imbalance among males during 
ACE2 receptor suppression, as in the presence of SARS-CoV-2 infection [35,37]. 
Interestingly, a quantitative variation in ACE1 levels has been demonstrated to be modulated 
also by the ABO-blood group locus (9q34.2). Moreover, selected ABO polymorphisms (rs495828, gene 
promoter, and rs8176746, exon 7) influence ACE inhibitors treatment response [90–92], and might 
contribute in reducing SARS-CoVs’ transmission, in terms of number of infected individuals and 
epidemic rate reduction. This ascribed to O-blood group a lower risk of infection, hypothesizing that 
natural anti-A and anti-B antibodies can contribute in protecting against viral diseases at the 
population level [93]. 
The ACE2 gene maps on chromosome Xp22.22, is 41.04 kb long, and contains 18 or 19 exons in 
two isoforms (Genbank, NT 011757), which differ in the presence of an extra exon in the longer 
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isoform at the 5′-end [51]. The ACE2 and ACE1 catalytic domains share 42% homology in their amino 
acid sequence and have a similar exon/intron organization, indicating a common ancestor. Among 
the several gene variants [94], particular attention has been paid to the transition G8790A (rs2285666) 
in intron 3 of the ACE2 gene, previously investigated in association studies with hypertension, 
although some issues remain almost inconclusive [95,96]. Unlike autosomal genes (i.e., ACE1), X-
linked genes (i.e., ACE2) cannot show in males any advantageous heterozygous condition in case of 
mutations or polymorphic at-risk conditions. Accordingly, in the presence of a lower activity of the 
ACE2 gene, as for the one associated with the 8790 G-allele [97,98], male-carriers are certainly 
hemizygotes unable to compensate with the 8790 A-allele counterpart. ACE2 G8790A is located at the 
beginning of the intron 3, theoretically affecting gene expression with alternative splicing 
mechanisms [99,100], also having a strong linkage disequilibrium with other SNPs (rs1978124 intron 
1 and rs714205 intron 16) in the ACE2 gene [101,102]. 
An interesting recent paper investigated the ACE1 I/D variant in combination with the ACE2 
G8790A transition in hypertensive population. The authors hypothesized that patients characterized 
by higher ACE1 activity (i.e., D/D-genotype) in conjunction with reduced ACE2 activity (i.e., GG-
females or hemizygous G-males) could account for increased susceptibility to hypertension mainly 
in association with classical cardiovascular risk factors such as old age, dyslipidemia, and diabetes 
[97]. 
Noticeably, it emerges that an overly activated RAS, exacerbated by genetic predispositions 
affecting the ACE1/ACE2 balance and in combination with advanced age and classic acquired 
cardiovascular risk conditions, might lead to systemic disorders and/or severe local disturbances of 
the normal tissue homeostasis. Overall, this condition can establish a complex multistep mechanism 
(Figure 3) leading to organ dysfunction such as in SARS-CoVs where the ACE1/ACE2 equilibrium is 
destroyed and incidentally worsened by the suppression of the ACE2 receptor due to SARS-CoV-2 
binding, and/or ADAM17 activity, and/or by the combination of specific ACE1/ACE2 at risk 
haplotypes [35,37,48,71,103]. 
 
(a) 
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Figure 3. Hypothesized mechanism of a genetic–environmental interaction between ACE1/ACE2 
genes and SARS-CoV-2 infection. (a) Normal-health condition with a balanced RAS, normal Ang-II 
levels (Ang-II ↓↑), in the absence of virus infection. (b) Over-expression of ACE1 receptor as in the 
presence of the ACE1 DD-genotype (i.e., rs4646994, rs1799752, rs4340, rs13447447) in combination 
with ACE2 downregulation due to SARS-CoV-2 infection and/or in the presence of the ACE2 8790 G-
allele (i.e., rs2285666), resulting in ACE1/ACE2 unbalancing, RAS over-activation (Ang-II ↑) and lung 
shut-down. (c) Under-expression of ACE1 receptor as in the presence of the ACE1 II-genotype (i.e., 
rs4646994, rs1799752, rs4340, rs13447447) in combination with ACE2 downregulation due to SARS-
CoV-2 infection counteracted by the ACE2 8790 A-allele (i.e., rs2285666), resulting in ACE1/ACE2 re-
balancing, no RAS over-activation, re-balanced Ang-II levels (Ang-II ↓↑), and no lung shut-down. 
ADAM17: metallopeptidase domain 17; ARBs: angiotensin receptor blockers; MRAs: 
mineralocorticoid receptor antagonists. 
Our hypothesis should be demonstrated by dedicated clinical epidemiological studies in 
genetically selected patients, though it is to be taken into account that the above described ACE1 and 
ACE2 gene variants do not completely lessen the enzyme levels. Rather, they are responsible for a 
medium–mild reduction with enzyme levels within the low–normal range of the general population. 
Nonetheless, in critical conditions and co-morbidities (e.g., SARS-CoV-2 infection), selected genetic 
variants might favor RAS-rebalancing. Moreover, among COVID-19 patients, those taking RAS-
inhibitors may take advantage of the treatment considered an adjuvant drug for RAS rebalancing 
[40,75]. 
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Finally, the surface of SARS-CoV-2 interacts specifically with ACE2 through its receptor binding 
domain (RBD) of the S-protein, which is critical to the success of the viral infection. The affinity 
between ACE2 and the RBD of the SARS-CoV-2 is 10–20 times higher than that of previous SARS-
CoVs, which also explain its higher aggressive performance [104,105]. Moreover, the ACE2 peptidase 
domain (PD), normally deputed to Ang-I to Ang 1–9 cleavage, also makes available a direct binding 
site for SARS-CoV-2 S-proteins. In addition to the PD domain, a neck domain is also crucial for the 
ACE2 dimerization process and stability. Extensive polar interactions have been recognized in the 
neck domain of ACE2, and the complex network of polar interactions between amino acid residues 
ensures a stable and functional dimer assembly. Several gene polymorphisms have been listed among 
those amino acid residues suggested to be crucial for dimer stability in the PD and neck domains of 
the ACE2 gene [106,107]. Theoretically, this might interfere with the ACE2-SARS-CoV-2 interaction, 
especially in females who have two different ACE2 genes within the two different X-chromosomes, 
a condition that may give rise to a greater structural variability in females, who potentially assemble 
“hetero-dimers”, particularly in the presence of a skewed X-chromosome inactivation (XCI), in 
comparison to males who necessarily assemble “homo-dimers”. Obviously, XCI is not the same in 
every female, being potentially advantageous or not in terms of virus cell entry. Moreover, a 
difference in the open or closed conformation of the ACE2 receptor together with the glycosylation 
rate of some amino acid residues in the PD domain could affect ACE2-SARS-CoV-2 interaction 
[105,108], as demonstrated by chloroquine treatment of SARS-CoV patients, in which chloroquine 
inhibited virus infection by interfering with the terminal glycosylation of ACE2 receptor [109]. 
Accordingly, we have previous experience of dimeric/tetrameric molecules in which selected SNPs 
seemed to have higher detrimental effects on the molecule structure and activation when combined 
heterozygous haplotypes were co-inherited in the same carrier rather than in homozygous 
polymorphic individuals [110–116]. 
3. Immune Processes: An X-Related View 
Sex-disparities have been often observed in response to communicable diseases [107,117]. In 
viral infections, sex differences in term of intensity, prevalence, severity, and mortality have been 
reported depending on the etiological agent, as reviewed in [118]. The general tendency in females 
is, however, to show a greater humoral and cell-mediated immune response to infection [117–119]. 
Consequently, females clear infections more quickly and more effectively than males [118,120,121]. 
Sex hormones can be partly responsible for this phenomenon: by binding to specific receptors on 
immune cells, they can trigger their activity (estrogen) or suppress it (testosterone) [119,122,123]. 
However, sex differences may also be due to an imbalanced expression of genes on the X- and Y-
chromosomes, since immune-related X-linked genes appear to be more activated in female immune 
cells. 
The sex chromosomes X and Y, which differentiated from ordinary autosomes about 180 million 
years ago, show great levels of dissimilarities, except in their pseudo-autosomal regions (PAR1 and 
PAR2) located at the end of both chromosomes [123]. Having two X-chromosomes, females have two 
different cell types in all their organs with one of the two X-chromosomes being inactivated (Xi, while 
the activate form is Xa), a condition that was first described by Mary F. Lyon in mice [124]. The XCI 
is due to epigenetic processes that randomly select and permanently silence one of the two X-
chromosomes of a female individual. The process occurs at an early phase of embryonic development 
and is maintained during adulthood. XCI is a strategy that aims to balance the X-linked 
transcriptional dosage between female XX and male XY cells. In general, 50% of female cells and all 
cells derived from them have the maternal X-chromosome inactivated, the other 50% have the 
paternal X-chromosome inactivated. The knowledge of the complex mechanism of XCI and its 
regulation is summarized in [125]. XCI results in a condition of “cell mosaicism” in a female 
individual, where a balanced expression of both parental X-linked genes is expected [126]. This 
condition may provide females with greater plasticity and adaptability in the response to infectious 
diseases than males. When it comes to gene expression, females may compensate adverse X-linked 
mutations by using cells that carry the wild allele on the other X-chromosome [124]. However, it is 
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clear that XCI is incomplete in humans [127] and that the balance may be disrupted both by the 
process of skewed XCI and by genes escaping silencing [123]. 
Skewed X-chromosome inactivation appears when one X-chromosome is favored over the other 
for XCI. This may result in 75–90% of cells with the same parental X-chromosome silenced. This 
predominance of one Xi also causes unbalance of the allelic dosage and of X-linked transcription. This 
loss of mosaicism may lead to a reduced plasticity of the immune system and a loss of immunological 
memory [126]. There are several mechanisms underlying skewed XCI which appear to be partly age-
dependent, showing an increment in older women, at least in the blood, which is also associated with 
smoking [126]. 
With regard to the mechanism of escaping silencing, it seems that about 15% of X-linked genes 
can escape inactivation, so that they are expressed by both X-chromosomes in female cells, whereas 
a further 10% vary among individuals for their silencing behavior. The level of expression is, 
however, always lower in the escaped gene [128]. XCI escape signatures vary between individuals, 
even during growth and aging, as well as between cells in a tissue [128]. 
In humans, naïve mature B and T cells were demonstrated to lack XCI on some genes 
(H3K27me3, H2A-ubiquitin, H4K20me and macroH2A), which are again partially silenced 
(H3K27me3 and H2A-ubiquitin) when lymphocytes are activated [117]. Other immune cells have 
shown evidence of different XCI maintenance in females, as summarized in [117]. Essentially, the 
results of different studies now support the theory that sexual dimorphism of immune cell is 
triggered by XCI escape mechanisms [117]. In particular, the distal end of Xp and PAR regions, which 
contain the highest number of immune-associated genes on the X-chromosome, have a higher chance 
of escaping XCI [123]. 
Accordingly, in the ACE2 gene maps of the Xp-region and in a study carried out without 
distinguishing between male and female cells [39] it was demonstrated that ACE2 is abundantly 
present in human lung epithelia and small intestine enterocytes, while another study [36] has shown 
that the expression of the ACE2 receptor is higher on oral mucosa and tongue epithelial cells. A 
systematic survey of XCI that integrated transcriptomes with genomic data [127] identified ACE2 as 
a tissue-specific escape gene that showed moderate male-biased expression in lungs, higher male-
biased expression in the small intestine, and weak male-biased expression in Epstein–Barr virus 
(EBV)-transformed lymphocytes. This finding may be suggestive of lower ACE2 expression in 
females due to the combination of the two X-linked genes compared to the expression arising from 
the X-linked and a Y homologue in males [127]. Nevertheless, in another recent study [129], no sex-
mediated differences in expression were found between the sexes. Alternatively, the predominant 
male-biased expression of ACE2 might be explained by increased ACE2 activity in males partially 
driven by sex hormones [127], as it has recently been demonstrated in mice kidneys [130]. 
Finally, strong results have recently been found in favor of an exceptionally high basal level of 
ACE2 in Asian females than in other ethnic groups and an age-dependent decrease more significant 
in men than women [131]. Briefly, this study shows an apparent negative correlation between ACE2 
quantitative expression and infection susceptibility and severity at population level [131]. 
Nevertheless, the tissues they have tested are not those of the upper respiratory tract, with the 
exception of the lung (and blood vessels) which only show a moderately higher ACE2 expression in 
East Asian females. The authors’ conclusion that Asian women are more protected against CoVs than 
men is based on the hypothesis that ACE2 repression induced by SARS-CoV2 might be counteracted 
by high basal levels of ACE2 induced by higher levels of sex hormones (which decrease with age) 
and reduced by systemic inflammation [131]. This fascinating theory, which would support the 
hypothesis of ACE1/ACE2 unbalance on ARDS onset in COVID-19 patients, needs to be confirmed 
in the future when more data will be available. 
4. Inflammatory Processes: An X-Related View 
Sexual dimorphism in terms of risk, susceptibility, and prognosis has been reported for several 
inflammatory pathological conditions, including respiratory diseases in which hormonal profile, 
genetic, and epigenetic factors may play a role [8,27,132]. In this scenario, it is relevant that the 
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response to vaccination seems to be improved in females who therefore show a lower 
risk/vulnerability to several pathogens, while males are more exposed and at higher risk [133]. 
Furthermore, evidence suggests that males tend to experience the worst prognosis in acute 
inflammatory settings (e.g., sepsis) [134,135], while there is a generalized inversion of prognosis 
between men and women in chronic inflammatory conditions (e.g., asthma) [136,137]. In relation to 
SARS-CoV2, the accumulation of reports and epidemiological data indeed confirms that, in 
agreement with other respiratory inflammatory diseases and consistent with previous MERS-CoV 
and SARS-CoV infections, the new coronavirus preferentially affects males than females that show a 
better prognosis [138–140]. 
The onset of inflammatory processes is a key pathological feature of SARS-CoV-2 infection. The 
massive release of inflammatory cytokines and chemokines in COVID-19 patients was first reported 
by Huang and colleagues, showing in particular higher levels of IL2, IL7, IL10, GSCF, IP10, MCP1, 
MIP1A, and TNFα in the peripheral blood of intensive care unit (ICU) patients compared to non-ICU 
patients [141]. The impact of the “inflammatory-wave” in COVID-19 suggests that the cytokine storm 
might be strongly associated with the severity of the disease [141]. The role of the cytokine storm in 
SARS-CoV-2 infection is attracting great attention as a crucial phase to investigate in order to clarify 
the disease’s pathogenic process (e.g., to elucidate the role of Th1 and Th2 responses) and to identify 
new therapeutic targets (see the published results and the ongoing clinical trials with Tocilizumab, a 
monoclonal antibody targeting the IL-6 pathway) [141–143]. Sex hormones have been suggested as 
potential mediators of the reported sexual dimorphism by virtue of their ability to modulate innate 
and adaptive immunity, as previously reported [144] and as described above. However, since sex 
dimorphism observed in several inflammatory diseases, including respiratory pathologies, has also 
been confirmed in studies dealing with pre-pubertal cohorts [145–147], there is growing consensus 
on the need to consider additional factors/variables that may occur. Similarly, there is growing 
evidence suggesting that the X-chromosome and X-linked genes are the main determinants of the 
reported sex dimorphism in disease susceptibility and prognosis [8,148]. The X-chromosome carries 
about 1,200 genes [149] including cytokines/cytokines receptors, toll-like receptor (TLR)-mediated 
signaling pathway genes, NF-kB and MAPK signaling genes, genes involved in apoptosis, genes 
involved in redox balance, and other immune-modulators such as CD40 ligand and FOXP3, as 
recently reviewed [150]. 
With regard to the role of the number of X-chromosomes on inflammation and release of 
inflammatory cytokines, in a recent work Lefèvre and colleagues addressed how the number of X-
chromosomes can affect the secretion of inflammatory cytokines after the activation of the TLR 
signaling pathways [151]. The authors demonstrated that cytokine production in response to 
different TLR ligands was improved in males, showing higher inflammatory response than in females 
and subjects with Klinefelter syndrome who carry two X-chromosomes, but are characterized by a 
hormonal profile more similar to that of males [151]. The presence of two X-chromosomes carrying 
genetic variants of X-linked inflammatory genes/receptors undergoing random inactivation may 
therefore represent an advantage in the acute phase of inflammatory diseases [151,152]. 
Finally, X-linked genes coding for inflammatory mediators/receptors may also escape XCI 
leading to bi-allelic expression [153], with strong implications in sex-related differences of 
inflammatory responses [154]. Interestingly, the X-linked ACE2 gene, in transgender males treated 
with estrogen therapy and androgen antagonists shows significantly higher expression and increased 
number of cells expressing ACE2 among testicle cells [131]. Overall, if inflammation is needed to 
control the invasion/elimination of pathogens, the onset of exacerbated inflammatory responses may 
be harmful and lead to tissues/organs damage. In this scenario, females result as better “armed” 
thanks to the presence of a cellular mosaicism that may be more than useful to modulate/balance 
inflammation [150]. 
The lessons learned from different respiratory diseases of viral and non-viral origin, and 
preclinical research suggest that the number of active X-chromosomes can make a difference in 
shaping the type, dimension, and lasting of inflammatory responses that, in synergy with sex 
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hormones, may account for the low risk and better prognosis of SARS-CoV-2 infection in females, 
though a multidisciplinary approach for such complex condition is mandatory. 
5. Habits, Gender and Environmental Related Risks 
According to international disaggregated data, men are faring worse than women in COVID-19 
pandemic [155]. On the other hand, the long-term coronavirus fallout may be worse for women than 
for men due to social, psychosocial, and occupational reasons as well as environmental factors and 
differences in lifestyle. Biological and behavioral causes directly or indirectly play a role in modifying 
women’s risk such as different comorbidity rates (e.g., hypertension and cardiovascular diseases), 
smoking and drinking habits, personal hygiene, the number of females among nurses and caregivers 
both in hospitals and within families, and of course pregnancy and motherhood, just to cite the most 
relevant. 
Within the several habit-related factors, smoking deserves particular consideration. Smoking is 
a risk for many respiratory diseases and undoubtedly also for COVID-19 [155,156]. The European 
Respiratory Society [157] reported results of different studies concluding that smokers are 14 times 
more likely to die from COVID-19 [158,159], but only a few studies definitely advise to stop smoking 
[160] and, to our knowledge, no country has taken strong prevention measures. As regards the 
individual susceptibility of smokers toward respiratory diseases, such as influenza, chronic 
obstructive pulmonary disease (COPD), tuberculosis (TB), or other lung pathological conditions, 
there are no doubts about a direct association [161–164]. Accordingly, the European Centre for 
Disease Prevention and Control (ECDC) suggested that smoking may contribute to increasing the 
number of severe COVID-19 cases [165]. Conversely, it has been speculated that smokers seem less 
likely to develop COVID-19, by the hypothesis that smoke exposure might modulate the immune 
response and the levels of inflammation markers. By attenuating the physiological defense of the 
immune and inflammatory system, smoking might paradoxically mount a less aggressive cytokine 
storm [166]. Accordingly, a “nicotinic hypothesis for COVID-19” has been speculated, suggesting the 
use of nicotine-patches on coronavirus patients [167]. Overall, no evidence exists that smoking 
protects COVID-19 patients from developing severe symptoms and recent metanalyses indeed list 
smoking habits as risk factors [168–170]. Of note, it has been reported that the ACE2 receptor is 
upregulated in the lungs of smokers or COPD patients, including small airway epithelium, brush 
borders, type-II alveolar pneumocytes and alveolar macrophages [171,172]. The expression was more 
evident in patients with COPD compared to never-smokers, suggesting that smoking upregulates 
ACE2 expression and COPD further exacerbated it, hypothesizing in them an amplified susceptibility 
for COVID-19. 
Environmental and health issues may result associated with COVID-19 and some of them 
deserve to be mentioned [173]. First of all, air pollution and poor air quality has been suggested to 
lead to an increased COVID-19 infection rate probability due to a direct effect of air pollution on 
humans [174]. Moreover, other studies on flu-like viruses highlighted the potential role of pollen in 
the atmosphere, that by increasing general immune responses might affect viral spread, speculating 
that it might also decrease during warm seasons [175]. Hospitals are crucial in COVID-19 pandemic 
containment and controlling, and for dedicated disinfection techniques for infrastructures personnel 
and medical equipment are key issues [176] to avoid front-line healthcare worker infection risk and 
increased psychological burden, particularly for medical doctors and nurses among which women 
account for the largest number worldwide [177]. Overall, protective measures for people at such a 
high risk as hospital workers is of primary importance. Efficient personal and protective equipment 
reduces mortality, and we need to plan strategies to ensure protection also against infections rising 
from environmental sources. Therefore, any useful tool/instrument/product/action should carry a 
global benefit. 
Finally, considering individual genetic susceptibility or environmental influences on virus 
infection and/or SARS progression, a wide and heterogeneous geographical distribution of absolute 
numbers and percentages of infected cases is now emerging. Different clinical phenotypes and 
symptoms characterize not only different populations and countries, but also close geographic 
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regions in which opposite situations may coexist. As a paradigmatic example, according to data from 
“Dipartimento Protezione Civile COVID-19 Italia” [178], our region, Emilia Romagna, is the second area 
of Italy for absolute number of SARS-CoV-2 infections (26,487 confirmed cases/4,452,638 habitants; 
male/female ratio 48.6/51.4). It accounts for an overall infection rate of about 0.59%, characterized by 
3,366 deaths (14.2% death rate), considering 217,039 performed tests and 1899 total recovered patients 
(7 May 2020, 7:00 PM). Among the towns belonging to the same region, Ferrara shows the lowest 
percentages (960 confirmed cases/346,975 habitants; male/female ratio 48.1/51.9) accounting for an 
overall infection rate of about 0.27%, compared with the town of Piacenza (less than 200 Km far from 
Ferrara) which has the highest rate (4300 confirmed cases/286,781 habitants; male/female ratio 
48.9/51.1) accounting for an overall infection ratio of about 1.5% (Ferrara vs. Piacenza; p< 0.00001; 
Ferrara vs. rest of the region; p < 0.00001). Obviously, other variables also need to be analyzed, first 
the local containment actions, the number of tests performed and then the geographic locations. In 
this regard, Piacenza is very close to the most critical hot-spot of the infection in Italy [region 
Lombardia (0.83%); Lodi (1.43%), Codogno area (red zone)] and other additional parameters such as 
population density may account for local differences in terms of viral spreading (Ferrara: 325 
habitants/Km2 vs. Piacenza 880 habitants/Km2). Genetic selection pressure by previous epidemics, 
such as the long-lasting malaria epidemics in the Po river area where the city of Ferrara is located, 
cannot be excluded. This is in line with some publications reporting that endemic malaria seems to 
protect from COVID-19 outbreak and that genetic variations associated with malaria (e.g., ACE2 and 
ABO genes) may play protective roles [179–181]. 
In summary, individual susceptibility, mainly driven by gene-environment interactions, has a 
great role in determining immunity, survival, and treatment responses in different populations. 
6. Conclusions 
The COVID-19 pandemic by coronavirus SARS-CoV-2, is a severe, complex, and multifactorial 
disease in which human genetics, due to inherited predispositions, could play a role together with 
pre-existing comorbidities and acquired risk conditions. Unmodifiable factors, such as age and sex, 
together with modifiable classical cardiovascular risk factors and comorbidities play crucial roles in 
tuning the fate of SARS-CoV-2 infection, worsening prognosis, and mortality rate. In turn, the 
mechanism of SARS-CoV-2 infection, due to ACE2 receptor entry, might be altered by individual 
genetic or developed susceptibility. An overly activated RAS-system, mainly due to local 
ACE1/ACE2 unbalancing, might be crucial in determining specific vulnerability/receptivity and in 
giving indicators of the local balanced inflammation, blood coagulation, and fibrinolysis. These 
evidences support the use of appropriate anticoagulant and anti-inflammatory therapies properly 
monitored by specific laboratory markers (as fibrin D-Dimer) or with a more refined approach by the 
dynamic assessing of residual FXIIIA levels, as recently suggested during any acute thrombotic event 
[182,183]. The unexpected reported higher expression of ACE2 in females, the inverse age-dependent 
ACE2 expression significantly reduced by the presence of diabetes, and the strong repression of ACE2 
by inflammatory cytokines, confirm an inverse correlation between ACE2 levels and SARS-CoV-2 
prognosis. Summarizing, this is in contrast with the assumption that “high ACE2 is a culprit in COVID-
19 outcome, and on the contrary supports a protective role of high ACE2 expression against SARS-CoV2 
fatality” [131] also strengthened by the ACE2 intrinsic anticoagulant properties. Interestingly, SARS-
CoV-2 mediated repression of ACE2 is counteracted by sex hormone inducible mechanisms (though 
unfortunately sex-hormones decrease with age) and exacerbated by systemic inflammation (which 
unfortunately increases with age and chronic diseases) [131]. 
Part of the present findings were already known from previous SARS epidemics, but the 
pandemic proportions of COVID-19 have led researchers and clinicians to fight together more than 
during previous SARS-CoVs infections. Accordingly, some aspects such as the sex gap in favor of the 
females, particularly for prognosis and survival, have been greatly deepened and investigated 
through epidemiological studies. Different sex and age groups have strongly different susceptibilities 
to infection and mortality, considering male-sex, old age, and comorbidities as the most affecting 
variables. In addition, genetic predispositions or inherited protective mechanisms have been 
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speculated to explain some controversial data. Considering individual genetic susceptibility to virus 
infection and progression, heterogeneous geographical distributions are now emerging not only 
among different populations and countries, but also between close geographic regions. 
In conclusion, while waiting for an effective and safe vaccine the main task is to understand the 
individual virus susceptibility/receptivity together with the repurposing of already available 
pharmacological compounds, such as selected anti-inflammatory, anti-malaria, and anticoagulant 
drugs as well as reconsidering RAS-antagonists in selected patients to achieve efficient and 
personalized targeted therapies. 
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